TG THERAPEUTICS INC (TGTX)
Health Care · biotechnology · NASDAQ
TG Therapeutics is a commercial-stage biotechnology company driving growth through its FDA-approved multiple sclerosis therapy, BRIUMVI, and an expanding pipeline of B-cell disease treatments.
What TG THERAPEUTICS INC does
TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on the development and commercialization of novel treatments for B-cell diseases. Its lead product, BRIUMVI (ublituximab-xiiy), is an FDA-approved anti-CD20 monoclonal antibody for the treatment of adults with relapsing forms of multiple sclerosis (RMS). The company is actively expanding its pipeline into other therapeutic areas, including myasthenia gravis and treatment-resistant schizophrenia.
Themes: multiple sclerosis (MS), B-cell therapies, monoclonal antibodies, neurology therapeutics
Fundamentals
- Price$56.01 as of 2026-08-24 close
- Market cap$8.6B as of 2026-08-24
- 1-year return+90.2% 2025-08-22 close $29.44 → 2026-08-24 close $56.01
- P/E20.40 as of 2026-08-24
- Net margin+55.2% as of 2026-08-24
- Gross margin+82.4% as of 2026-08-24
- ROE+72.3% as of 2026-08-24
- Debt / equity1.23 as of 2026-08-24
- Revenue growth (YoY)+76.1% as of 2026-08-24
- Revenue CAGR (3y)+504.9% SEC XBRL
- Beta0.67 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How TGTX compares in its sector
- price-to-earnings ratiomiddle range 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TGTX is not currently in any published Top 10 list. Its scores are below.
Long-term score
61.9 #216 of 1,605 scored · #27 of 195 in Health Care
Growth 99th (3-year revenue CAGR 504.9%, revenue growth year over year 76.1%) and long-term trend 80th (trading above its 200-day average); weakest is financial health (17th, free cash flow margin 2.2%, debt to equity 1.2).
Short-term score
45.6 #932 of 1,698 scored · #159 of 236 in Health Care
Volume and participation 82nd: trading volume is about normal versus its 30-day average; trend 70th: the price is 12% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is catalysts 29th: analysts have cut their average price target by 10.4% since the prior reading. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90). It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How TG THERAPEUTICS INC looks technically
TG THERAPEUTICS INC (TGTX) is trading 47.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 81 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-07-24, pushing above its recent trading range.
Trend
8
| Distance from the 200-day | it is trading 47.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +47.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $53.00 | $53.00 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $37.94 | $37.94 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 45.365. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 81 trading days ago — a "golden cross", a bullish long-term signal | 81 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($47.27 to $56.87) — its "stochastic" reading is 91 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 91.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $59.30 | $59.30 |
|---|---|---|
| From the 52-week high | it is 5.5% below its 52-week high (its highest price of the past year) | -5.5% |
| Above the 52-week low | it is 109.3% above its 52-week low (its lowest price of the past year) | +109.3% |
| Below the 52-week high | it is 5.5% below its highest point of the past year | 5.5% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-24, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $233.44 (set on 2010-05-04) | $233.44 |
| Given back of the 52-week move | over the past year its closes ranged ($26.94 to $59.06), and it has given back only a small part of its rise from last year’s low — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $38.18 to $39.21. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.5% |
| From the all-time high | it is 76.0% below its all-time high | -76.0% |
| Nearest price level | it is trading 2.6% below a resistance level at $57.48 — a price it turned at twice since 2026-06-22, most recently on 2026-07-27. Since 2024-08-26 it has 14 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.6% |
| All-time low | its lowest closing price on record is $0.9563 (set on 2011-12-29) | $0.9563 |
| Above the all-time low | it is 5757.3% above its all-time low | +5,757% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 47th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.57 between its high and its low — about 4.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.57 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $45.82 and $55.71 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $45.82 – $50.77 – $55.71 |
| Typical daily range (% of price) | its price moves about 4.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.6% |
| Stretch from the 200-day average | it is trading 7.0 daily ranges above its 200-day average price (47.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.25× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 10.4% since the prior reading | -10.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-24 2.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.0% |
|---|---|---|
| Open gap | it gapped 3.7% above the previous close 52 sessions ago and has not traded back through the level it left behind at 40.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.7% |
| Gap filled | a 2.7% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +10.78% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.4 percentage points (the stock lost 0.1% while the market gained 3.3%) | -3.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 41.7 percentage points (the stock gained 44.1% while the market gained 2.4%) | +41.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 72.5 percentage points (the stock gained 83.6% while the market gained 11.1%) | +72.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 71.9 percentage points (the stock gained 90.2% while the market gained 18.3%) | +71.9% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.2% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 12.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +4.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 38% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $40.61 — a volume-weighted average of daily closes over 161 sessions, not a true tick-by-tick VWAP. | +37.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-08-03 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $50.11 — a volume-weighted average of daily closes over 16 sessions, not a true tick-by-tick VWAP. | +11.8% |
Price levels it has turned at before
TGTX last closed at $56.01 on 2026-08-24. Since 2024-08-26 it has turned at 14 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $57.48 | Resistance | 2.6% above the last close | turned there twice · 2026-06-22 to 2026-07-27 |
| $51.22 | Support | 8.6% below the last close | turned there twice · 2026-07-02 to 2026-07-23 |
| $38.05 | Support | 32.1% below the last close | turned there four times · 2025-06-27 to 2026-05-19 |
| $36.62 | Support | 34.6% below the last close | turned there four times · 2024-11-14 to 2026-06-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $45.37.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 2 trading days, since 2026-08-21.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$69.71 range $21.00 – $86.00; median $75.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TGTX
- Consensus EPS estimate$0.328 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on the commercial success of BRIUMVI for substantially all of its revenue.","Risks associated with clinical trial outcomes and the timing of regulatory approvals for pipeline drug candidates.","Intense competition from established pharmaceutical companies with greater financial and marketing resources."]
What changed in the latest 10-Q
AI-assisted comparison of TGTX's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added 'Subcutaneous BRIUMVI' section under RECENT EVENTS describing Phase 3 trial completion of enrollment with topline data expected around year-end 2026 or first quarter 2027 (filed 2026-05-06)
- Added 'Financial Update' section under RECENT EVENTS detailing March 2026 $750 million senior secured credit facility with Blue Owl Capital, repayment of $250 million facility, net raise of $500 million, option for additional $250 million incremental capital, and Board authorization increasing share repurchase program from $100 million to $300 million with $200 million repurchased through April 30, 2026 (filed 2026-05-06)
- Added reference to February 2026 publication of five-year data from ULTIMATE I and II studies in JAMA Neurology (filed 2026-05-06)
- Added 'U.S. Commercialization of BRIUMVI and Market Dynamics' section with expanded discussion of competitive landscape, market positioning, and factors influencing adoption (filed 2026-05-06)
- Removed:
- Removed 'In September 2025, we completed our previously authorized $100 million share repurchase program' and related details about Prior Share Repurchase Program and 2025 Share Repurchase Program (filed 2025-11-05)
- Removed reference to 'Additional BRIUMVI data continues to be presented at major medical meetings. Most recently data was presented at ECTRIMS 2025, including six year long term data from the ULTIMATE I & II Phase 3 trials; updated data from the ENHANCE trial...and 2025 data from ENABLE' (filed 2025-11-05)
- Removed reference to 'In August 2025, we announced patient enrollment commenced into a randomized Phase 3 pivotal cohort to evaluate a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI in the ongoing ENHANCE trial' (filed 2025-11-05)
- Removed separate 'U.S. Commercialization of BRIUMVI' and 'Ex-U.S. Commercialization of BRIUMVI' sections with detailed information about FDA approval timing, European Commission approval, Neuraxpharm agreement terms, and international approvals (filed 2025-11-05)
- Removed 'Subcutaneous Ublituximab Overview' section describing Phase 1 trial initiation in August 2024, myasthenia gravis enrollment in January 2025, and Phase 3 pivotal program enrollment commencement in September 2025 (filed 2025-11-05)
- Reworded:
- Changed reference year from 'December 31, 2024' to 'December 31, 2025' for Form 10-K comparison (filed 2026-05-06)
- Changed company description from 'fully-integrated, commercial stage, biopharmaceutical company' to 'fully integrated, commercial stage, biotechnology company' (filed 2026-05-06)
- Changed product description from 'research pipeline of investigational medicines' to 'research pipeline' (filed 2026-05-06)
- Changed BRIUMVI approval description from 'to include' to 'including' for consistency (filed 2026-05-06)
- Changed Ublituximab Subcutaneous clinical trial status from 'Phase 3 enrolling' to 'Phase 3 completed enrollment' (filed 2026-05-06)
- Changed table reference date from 'September 2025' to 'March 2026' for OUR PRODUCTS clinical trial status summary (filed 2026-05-06)
- Notes:
- Older filing (2025-11-05) text appears truncated at end of 'Subcutaneous Ublituximab Overview' section, cutting off mid-sentence
- Complete comparison of 'U.S. Commercialization of BRIUMVI and Market Dynamics' section not possible as newer filing text appears to continue beyond the provided excerpt
Risk Factors
- Added:
- Newer filing adds 'or' between 'FDA' and 'any comparable regulatory authority' in opening sentence of first risk factor (filed 2026-05-06)
- Newer filing changes FDA approval date reference from 'December 28, 2022' to 'December 2022' (filed 2026-05-06)
- Newer filing adds phrase 'or commitments to the satisfaction of regulatory authorities' in risk factor heading (filed 2026-05-06)
- Newer filing adds 'Table of Contents' page number 38 after first risk factor discussion (filed 2026-05-06)
- Removed:
- Older filing contained 'Table of Contents' page number 28 (filed 2025-11-05)
- Older filing stated 'the risk that our products do not achieve an adequate level of acceptance' as explicit risk in second paragraph (filed 2025-11-05)
- Older filing listed only 'post-marketing requirements' in risk factor heading without 'or commitments' phrase (filed 2025-11-05)
- Reworded:
- Changed from 'U.S. Food and Drug Administration (FDA) or approval' to 'U.S. Food and Drug Administration (FDA) or any comparable regulatory authority' in opening sentence (newer filing 2026-05-06)
- Changed from 'and our ability to successfully overcome the risks associated with commercializing drugs in the biopharmaceutical industry, including the risk that our products do not achieve an adequate level of acceptance, remains uncertain' to 'and our ability to successfully overcome the risks associated with commercializing drugs in the biopharmaceutical industry remains uncertain' (newer filing 2026-05-06)
- Changed heading from 'We may be subject to limitations on the indicated uses or requirements to fulfill certain post-marketing requirements to the satisfaction of regulatory authorities' to 'We may be subject to limitations on the indicated uses or requirements to fulfill certain post-marketing requirements or commitments to the satisfaction of regulatory authorities' (newer filing 2026-05-06)
- Notes:
- Both filings appear to be truncated at the same point in the third risk factor paragraph
- Text comparison limited to content provided; full Risk Factors section may contain additional changes not visible in excerpts
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-11-24. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TGTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding TGTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 34,279,346
- Reported value $1,138,759,867
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TGTX had 29,317,926 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TGTX had 19.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.62 days to cover at the same settlement.
- Reported short interest (shares) 29,317,926
- Short interest (% of shares outstanding) 19.2%
- Prior settlement (shares) 30,686,240
- Reported change -4.46%
- Days to cover (reported) 13.62
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (RHHBY)
- Novartis (NVS)
- Sanofi (SNY)
- Biogen (BIIB)
- Bristol-Myers Squibb (BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TGTX vs…
TG THERAPEUTICS INC is found in…
TGTX ranks in…
Frequently asked questions
What does TG THERAPEUTICS INC (TGTX) do?
TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on the development and commercialization of novel treatments for B-cell diseases. Its lead product, BRIUMVI (ublituximab-xiiy), is an FDA-approved anti-CD20 monoclonal antibody for the treatment of adults with relapsing forms of multiple sclerosis (RMS). The company is actively expanding its pipeline into other therapeutic areas, including myasthenia gravis and treatment-resistant schizophrenia.
What sector is TG THERAPEUTICS INC (TGTX) in?
TG THERAPEUTICS INC (TGTX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are TG THERAPEUTICS INC's (TGTX) competitors?
Notable peers of TG THERAPEUTICS INC (TGTX) include Roche, Novartis, Sanofi, Biogen and Bristol-Myers Squibb. This peer set is informational only — not financial advice.
Is TG THERAPEUTICS INC (TGTX) overbought or oversold right now?
TG THERAPEUTICS INC (TGTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TGTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.